Anti-angiogeneic Target Therapy for Cancer with Vaccine Based on the Recombinant Chicken FGFR-1 in Tumor-bearing Mice  

作　　者：郑少萍 张俊志 郑少江 黄风迎 吴人亮 曹利民 谢明星 

机构地区：[1]Department of Ultrasonography, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology [2]Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology [3]Department of Pathology of the Affiliated Hospital and the Hainan Provincial Key Laboratory of Tropical Medicine, Hainan Medical College [4]Department of Immunology, School of Basic Sciences, Tongji Medical College, Huazhong University of Science and Technology

出　　处：《Journal of Huazhong University of Science and Technology(Medical Sciences)》2007年第2期120-123,共4页华中科技大学学报（医学英德文版）

基　　金：This work was supported by a grant from Hainan Provin-cial Natural Sciences Foundation (No.30321);partly sup-ported by the National Natural Sciences Foundation of China (No.30660055);Hainan Provincial Bureau of Health (No.2006-28)

摘　　要：To explore the anti-tumor effect of immunotherapy with recombinant protein vaccine based on FGFR-1 of chicken （cFR-1） in a mouse Meth A fibrosarcoma model, tumor volume and survival rate of the mice were observed at a 3-day interval. Microvessel density （MVD） was detected by immunohistochemistry. Auto-antibodies against self-FGFR-1 were detected by Western blotting and ELISA, respectively. The anti-FGFR-1 antibody-producing B cells （APBCs） were detected by enzyme-linked immunospot （ELISPOT） assay. Eighteen days after inoculation of tumor cells, the tumor volume was significantly smaller in cFR-l-immunized group than in mouse FGFR-1 （mFR-1） immunized group and normal saline （NS） control group （P〈0.05）, and the survival time was significantly longer in cFR-l-immunized group than in the control groups （P〈0.01）. MVD was significantly lower in cFR-l-immunized group than in mFR-1-immunized group and NS group （16.8 ±5.6 vs 64.6±1.8 and 59.6±8.7, P〈0.01）. Antibodies against self-FGFR-1 were found in mFR-1-immunized group, the major antibody subclasses were IgG1 and IgG2b. Compared with the two control groups, the numbers of APBCs in cFR-l-immunized group were significantly increased （P〈0.01） These results demonstrated that the cFR-1-related anti-angiogenesis protein vaccine could induce the production of auto-antibodies against self-FGFR-1, which futher inhibit angiogenesis and growth of solid tumor.To explore the anti-tumor effect of immunotherapy with recombinant protein vaccine based on FGFR-1 of chicken （cFR-1） in a mouse Meth A fibrosarcoma model, tumor volume and survival rate of the mice were observed at a 3-day interval. Microvessel density （MVD） was detected by immunohistochemistry. Auto-antibodies against self-FGFR-1 were detected by Western blotting and ELISA, respectively. The anti-FGFR-1 antibody-producing B cells （APBCs） were detected by enzyme-linked immunospot （ELISPOT） assay. Eighteen days after inoculation of tumor cells, the tumor volume was significantly smaller in cFR-l-immunized group than in mouse FGFR-1 （mFR-1） immunized group and normal saline （NS） control group （P〈0.05）, and the survival time was significantly longer in cFR-l-immunized group than in the control groups （P〈0.01）. MVD was significantly lower in cFR-l-immunized group than in mFR-1-immunized group and NS group （16.8 ±5.6 vs 64.6±1.8 and 59.6±8.7, P〈0.01）. Antibodies against self-FGFR-1 were found in mFR-1-immunized group, the major antibody subclasses were IgG1 and IgG2b. Compared with the two control groups, the numbers of APBCs in cFR-l-immunized group were significantly increased （P〈0.01） These results demonstrated that the cFR-1-related anti-angiogenesis protein vaccine could induce the production of auto-antibodies against self-FGFR-1, which futher inhibit angiogenesis and growth of solid tumor.

关 键 词：fibroblast growth factor receptor-l VACCINE ANTI-ANGIOGENESIS FIBROSARCOMA IMMUNOTHERAPY 

分 类 号：R73-3[医药卫生—肿瘤]